Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serum prostate-specific antigen after post-prostatectomy radiotherapy.

I D Kaplan1, M A Bagshaw

  • 1Department of Radiation Oncology, Stanford University Medical Center, California.

Urology
|May 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An automatic seed finder for brachytherapy CT postplans based on the Hough transform.

Medical physics·2004
Same author

Automatic detection of linear artifacts in medical images.

Medical physics·2004
Same author

Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2004
Same author

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis.

Cancer·2001
Same author

Feasibility and patient tolerance of a novel transrectal ultrasound hyperthermia system for treatment of prostate cancer.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2001
Same journal

"Editorial Comment on "Vaginal Estrogen Prescription is Associated with Reduced Rates of Serious Adverse Outcomes in Women of All Age Groups With Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis".

Urology·2026
Same journal

The True Oral History of Buccal Mucosal Grafts for Male Urethral Stricture Repair.

Urology·2026
Same journal

Preventing Postpartum Pelvic Floor Dysfunction: Clinical Evidence and Policy Gaps in U.S. Coverage of Pelvic Floor Muscle Therapy.

Urology·2026
Same journal

Editorial Comment on "Through the Eyes of the Applicant: A Qualitative Study of the Urology Residency Match".

Urology·2026
Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026
Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026
See all related articles

External beam radiotherapy after prostatectomy effectively controls local cancer in most patients. A rising prostate-specific antigen (PSA) post-treatment indicates a higher risk of developing distant metastases, particularly bone metastases.

Area of Science:

  • Oncology
  • Urology
  • Radiation Oncology

Background:

  • Radical prostatectomy is a primary treatment for prostate adenocarcinoma.
  • Residual or recurrent prostate cancer after surgery can be indicated by elevated serum prostate-specific antigen (PSA).
  • External beam radiotherapy (EBRT) is a therapeutic option for patients with detectable PSA post-prostatectomy.

Purpose of the Study:

  • To evaluate the efficacy of external beam radiotherapy in patients with residual prostate adenocarcinoma after radical prostatectomy.
  • To identify predictors of treatment success and risk factors for distant metastases following EBRT.
  • To define risk groups based on PSA trends for predicting metastatic disease development.

Main Methods:

  • Retrospective analysis of 39 patients treated with EBRT post-radical prostatectomy.

Related Experiment Videos

  • Assessment of pre-irradiation PSA levels and correlation with pathological findings (surgical margins, seminal vesicle/lymph node involvement, Gleason score).
  • Long-term follow-up to monitor local control, PSA trends, and development of distant metastases.

    • Main Results:

    • Local control was achieved in 38 out of 39 patients.
    • Elevated PSA pre-irradiation was observed in 37 patients, suggesting residual disease.
    • Pathological factors like positive surgical margins and high Gleason scores were associated with post-surgical PSA.
    • Two risk groups were identified: a high-risk group with rising PSA (18 patients) and a low-risk group with stable PSA (17 patients).
    • Bone metastases developed in 9 of 18 high-risk patients, while none of the low-risk patients developed metastases.

    Conclusions:

    • External beam radiotherapy is effective for achieving local control in patients with residual prostate adenocarcinoma after prostatectomy.
    • Post-radiotherapy PSA trends are crucial for stratifying patients into risk groups for distant metastases.
    • A rising PSA after EBRT is a strong predictor of metastatic disease, particularly bone metastases, highlighting the need for vigilant monitoring and potential further therapeutic strategies.